Preclinical in vitro and in vivo evidence for CD74-targeting as effective treatment strategy for cutaneous T cell lymphomas
Reecent Publication
A promising therapeutic approach for patients with cutaneous T-cell lymphoma (CTCL) was investigated in a new study in which the Division of Pharmacology at KL was also involved. The researchers were able to show that the surface molecule CD74 is frequently found in various CTCL subtypes - such as Sézary syndrome and mycosis fungoides. CD74 is therefore well suited as a target for so-called antibody drug conjugates (ADC), i.e. antibodies that specifically channel active substances into cancer cells. The tested drug STRO-001 was able to reliably kill CTCL cells in the laboratory and was also very effective in the mouse model - especially in combination with chemotherapy.
Costanza, M., Giordano, C., von Brünneck, A.-C., Zhao, J., Makky, A., Vinh, K., Montes-Mojarro, I. A., Reisinger, F., Forchhammer, S., Witalisz-Siepracka, A., Edtmayer, S., Stoiber, D., Yin, G., Horst, D., Fischer, A., Siebert, R., Nicolay, J. P., Yin, M., Janz, M., ... Mathas, S. (2025). Preclinical in vitro and in vivo evidence for CD74-targeting as effective treatment strategy for cutaneous T cell lymphomas. British Journal of Dermatology. Advance online publication. https://doi.org/10.1093/bjd/ljaf001
Agnieszka Witalisz-Siepracka PhD
Scientific Staff (PostDoc)
Department of Pharmacology
Sophie Rosa Edtmayer MSc PhD
Scientific Staff (PostDoc)
Department of Pharmacology
Univ.-Prof. PD MMag. Dr. Dagmar Stoiber-Sakaguchi
Head of
Department of Pharmacology